Effectiveness of intraoperative cell salvage combined with a modified leucocyte depletion filter in metastatic spine tumour surgery

Ya-nan Zong1†, Chuan-ya Xu1†, Yue-qing Gong2, Xiao-qing Zhang1, Hong Zeng1, Chang Liu1, Bin Zhang1, Li-xiang Xue2, Xiang-yang Guo1*, Feng Wei3* and Yi Li1*

Abstract

Background: To compare the effectiveness of intraoperative cell salvage (IOCS) combined with a modified leucocyte depletion filter (MLDF) with IOCS combined with a regular leucocyte depletion filter (RLDF) in eliminating tumour cells from blood salvage during metastatic spine tumour surgery (MSTS).

Methods: Patients with a known primary epithelial tumour who underwent MSTS were recruited for this study. Blood samples were collected in 5 stages: from the patients’ vein before anaesthesia induction (S1), from the operative field at the time of maximum tumour manipulation (S2), and from the operative blood after IOCS processing (S3) and after IOCS+RLDF (S4) and IOCS+MLDF (S5) processing. The polyploids of tumour cells in the blood samples were collected and counted with immunomagnetic separation enrichment and fluorescence in situ hybridization.

Results: We recruited 20 patients. Tumour cells were detected in 14 patients (70%) in S1, 16 patients (80%) in S2, 13 patients (65%) in S3, and 12 patients (60%) in S4. MLDF was added in 8 patients. Tumour cells were detected in only 1 of 8 patients in S5 (12.5%). There were significantly fewer tumour cells in the samples collected after MLDF processing (S5) than in the samples collected after RLDF (S4) and around the tumour (S2) (P = 0.016 and P = 0.039, respectively). Although no significant difference was observed between S4 and S1, a downward trend was observed after IOCS+RLDF processing.

Conclusions: Tumour cells could be removed by IOCS combined with RLDF from blood salvaged during MSTS, but residual tumour cells remained. The findings support the notion that MLDF eliminates tumour cells more effectively than RLDF. Hence, this technique can be applied to MSTS.

Trial registration: ChiCTR1800016162 Chinese Clinical Trial Registry.

Keywords: Intraoperative cell salvage, Modified leucocyte depletion filter, Regular leucocyte depletion filter, Metastatic spine tumour surgery

Background

Blood loss in spinal surgery, resulting from tumour hypervascularity, dilated epidural venous plexus, soft tissue paraspinal blood vessels, and even uninvolved bone, is still a major problem, especially in metastatic spine tumour surgery (MSTS) [1]. Currently, blood loss occurring in patients undergoing major tumour surgery is mainly replenished by allogeneic blood transfusion.
purposes only at present. Although there have been sev-
device compared with RLDF and is used for research
modified LDF (MLDF, 18 μm) [8]. MLDF is an improved
this technique is still in its infancy in MSTS; thus, we con-
Intraoperative autotransfusion combined with blood irradiation or LDF could be a promising tech-
technique for the treatment of profuse haemorrhage in onc-
logic surgery [5]. Prospective studies have shown that
IOCS alone was successful in removing tumour cells in
nearly 90% of the samples and that the combination of
IOCS and LDF was more effective in removing tumour
cells from blood salvaged during MSTS [6, 7]. However,
this technique is still in its infancy in MSTS; thus, we con-
ducted this study. Considering that the tumour cells in
the blood are of different size due to different pathologic
types of primary tumours, filters of two pore sizes were
used in the experiment, regular LDF (RLDF, 40 μm) and
modified LDF (MLDF, 18 μm) [8]. MLDF is an improved
device compared with RLDF and is used for research
purposes only at present. Although there have been sev-
eral reports of RLDF and IOCS for MSTS, the study of
MLDF reports is still in the exploratory stage. Currently,
few studies have reported the application of combined
IOCS and MLDF in MSTS. The purpose of this study was
to analyse the ability of IOCS-MLDF to eliminate tumour
cells and to evaluate the safety of autotransfusion based
on laboratory test results in patients with MSTS.

Methods
Study design and study population
We recruited patients with metastatic spinal tumours
who underwent spinal surgeries between May 2018 and
May 2019 at our university hospital. The exclusion cri-
criteria were the presence of haematological or infectious
diseases and not consenting to participate in the study.
This study was approved by the ethics committee of
Peking University Third Hospital with approval number
LM2018020. The patients provided written consent. All
methods were carried out in accordance with Declara-
tion of Helsinki. Patient demographic information was
recorded.

Sample collection
The suction tube and blood reservoir of the IOCS
machine (Cell Saver 5+; Haemonetics Corporation,
Braintree, MA, USA) were rinsed and pre-filled with
200 mL of anticoagulant saline (heparin saline, 30 IU/
ml). The negative pressure of the suction device was
set at 120–150 mmHg. The anticoagulant drip rate was
adjusted to approximately 100 drops/minute, and the
flow rate was adjusted according to the amount and
speed of the recovered blood. All intraoperative shed
blood was recovered from the skin incision to remove
the tumour. The recovered blood was anticoagulated and
washed with sterilised saline (2000 mL for 125 mL of red
blood cells). Only salvaged blood with a haematocrit of
30–60% and volume greater than 100 mL was eligible for
use.

Two types of leucocyte reduction filters (RLDF and
MLDF) were used in this experiment. The RLDF had
a bore diameter of 40 μm (SB; Haemonetics Corpora-
tion). The MLDF had a bore diameter of 18 μm (Separa-
tor Haemo-Technology Beijing Co Ltd., Beijing, China).
In the initial experiment, 12 patients were recruited with
IOCS+RLDF, and it was found 5 patients (42%) still had
residual tumour cells detected at S4 stage. In order to dis-
cover more effective methods, we consulted the literature
and improved RLDF with MLDF, which had a smaller
pore size. In the subsequent experiment, 8 patients
were recruited and the blood was filtrated after IOCS
process with RLDF and MLDF. Overall, 20 patients had
IOCS+RLDF, in which 8 cases were treated additionally
with IOCS+MLDF. Blood products treated with IOCS-
LDF were used only for research purposes and not trans-
fused to patients.

Blood samples were collected in 5 stages: S1, blood
collected from the peripheral vein before the skin inci-
sion; S2, blood collected from the operative field at the
time of maximum tumour manipulation; S3, IOCS
blood collected after washing and before filtration
using the LDF; S4, blood collected after filtration using
IOCS+RLDF; and S5, blood collected after filtration
using IOCS+MLDF. Twelve millilitres of blood were col-
clected at each stage, which comprised 3 separate 4-mL
samples collected at slightly different time points to
avoid sampling error (Fig. 1). And the 3 samples taken at
each stage were then pooled for laboratory analysis. All
blood samples were stored in ethylenediaminetetraacetic
acid-coated vacutainer tubes (Becton–Dickinson, Franklin Lakes, NJ, USA), and the tubes were stored at 4°C.

**Laboratory methods**

The polyploids of tumour cells in blood samples were collected and counted using immunomagnetic separation enrichment and fluorescence in situ hybridization (FISH). Tumour cells from blood samples were enriched using a human peripheral blood leucocyte removal kit (Cyttel®, Jiangsu, China). After centrifugation of blood samples, the red blood cells were lysed and the white blood cells were removed using CD45 immunomagnetic beads. CD45 expression was detected in the remaining cells by immunofluorescence staining to further exclude the remaining leucocytes. Probes were utilized to identify centromeres of chromosomes 8 and 17 or 7. FISH was used to determine the number of chromosomes. When the number of chromosomes 8, 17, or 7 exceeded 2, the cell was classified as aneuploid and determined to be a tumour cell. Chromosome enumeration probe 8 (CEP 8) was utilized for the detection of samples from various cancer types [9]. At the same time, chromosome 7 (CEP 7) was counted in renal [10], colon [11], oesophageal [12], and prostate [13] cancer cells, whereas chromosome 17 (CEP 17) was counted in endometrial and breast [14] cancer cells. The results were examined and judged by 2 independent pathologists.

**Statistical analysis**

All data were analysed using SPSS 24.0 (IBM Corporation, Armonk, NY, USA.). Measurement data conforming to the normal distribution and homogeneity of variances are expressed as the mean ± standard deviation. Non-normally distributed data are expressed as the median (interquartile range). Within-group comparisons were performed using Wilcoxon analysis. \( P < 0.05 \) was considered statistically significant.

**Results**

**Baseline and procedural characteristics**

Between May 2018 and May 2019, 24 patients with metastatic spinal cord compression were enrolled. The IOCS-LDF device was used during surgery. Four patients were excluded because of insufficient blood samples and presence of osteosarcoma as detected on postoperative pathology. Surgical sites included the cervical vertebra (5 cases), cervicothoracic vertebra (1 case), thoracic vertebra (10 cases), and lumbar vertebra (4 cases). The average age of the 20 patients (12 men and 8 women) was 57.55 ± 9.71 years. And none of them had preoperative segment vascular embolism. All 20 patients underwent MSTS (intralesional resection), of which 11 cases were decompression and 9 cases were debulking. The surgical duration was 138.4 ± 47.06 minutes. The average volumes of blood loss, red blood cell transfusion, and autologous blood recovery were 392.5 ± 270.61, 280 ± 293.08, and 196.25 ± 135 mL, respectively (Table 1).

---

**Fig. 1** Stages of blood samples collection during surgery. There are 5 stages for blood sample collection. S1, peripheral venous blood before skin incision (4ml*3 samples); S2, blood sampled from the operative field at the time of maximum tumour manipulation; S3, IOCS blood after washing and before LDF filtering; S4, blood sample after IOCS+RLDF filtration; and S5, blood sample after IOCS+MLDF filtration. 12 ml blood sample was collected which comprised three separate 4 ml sample taken at slightly different time points to avoid sampling error.
Medical history of the primary tumour

The origin of the primary lesions was mainly in the lungs (6 cases), gastrointestinal tract (6 cases, including 2 in the colon, 2 in the oesophagus, 1 in the rectum, and 1 in the ampulla), breasts (3 cases), thyroid (2 cases), endometrium (1 case), nasopharynx (1 case), and renal (1 case) (Table 2), which were confirmed by pathological evaluation of paraffin sections stained with haematoxylin-eosin and by immunohistochemistry (Fig. 2). Of the 20 patients recruited, 7 underwent primary tumour resection, 9 had a history of chemotherapy, 1 had a history of targeted therapy, 2 had a history of radiotherapy, all for primary tumours. All radiotherapy and chemotherapy had little impact on the number of tumour cells in the blood samples (Table 3).

Detection of tumour cells

Overall, 88 samples from 20 patients (including 20 samples each for S1, S2, S3, and S4 and 8 samples for S5) were analysed. After excluding CD45+ leucocytes using immunomagnetic beads (Fig. 3), aneuploidy (abnormal chromosome numbers) was detected in CEP 8, CEP 17, or CEP 7 by FISH. Tumour cells were recognized and counted using immunofluorescence staining and FISH. Negative expression of CD45 and aneuploidy of CEP 8, CEP 17, and CEP 7 were considered to indicate malignant cells (Fig. 3).

Ability of MLDF and RLDF to eliminate tumour cells

The number of tumour cells in all of the samples is shown in Table 1 and Fig. 4. Tumour cells were detected in S1 in 14 patients (70%), S2 in 16 patients (80%), S3 in 13 patients (65%), and S4 in 12 patients (60%) (Table 1 and Fig. 4A). In 8 patients, MLDF was used, and tumour cells were detected in only 1 patient (12.5%) in S5 (Table 1 and Fig. 4B). There was no significant difference between S4 and S1 ($P=0.165$) or between S4 and S2 ($P=0.426$), although a downward trend appeared after IOCS+RLDF processing. The number of tumour cells was significantly lower in the S5 samples after MLDF processing than in the S4 and S2 samples ($P=0.016$ and $P=0.039$, respectively). The number of tumour cells was not significantly increased in S5 compared to S1 ($P=0.102$).

Discussion

Blood loss during MSTS remains challenging, although minimally invasive surgical techniques have greatly improved. Blood loss varies greatly depending on the primary tumour of spinal metastases, surgical approaches, and operative time [2]. Recently, Kumar et al. found that the mean bleeding volume was 870 ± 720 mL, and the average blood transfusion volume was 1.5 ± 1.9 U in MSTS [2]. Even in minimally invasive spinal metastatic tumour surgery, the average bleeding volume has been reported as 745 mL (184–1320 mL) [15]. In the present study, the average volume of blood loss was 392.5 ± 270.61 mL, which is less than that reported in other studies. Eleven patients received ABT with an average transfusion volume of 280 ± 293.08 mL. The prevalence of anaemia in patients with cancer is reported to be approximately 40% [16] due to nutritional deficiency, chronic disease, blunted response to erythropoietin, bone marrow suppression either due to cancerous cells or as a side effect of chemotherapy/radiotherapy, and other causes [17]. Transfusion requirements are usually larger than expected. Thus, the investigation of IOCS+LDF is valuable for patients.

There is still controversy around the clinical safety of using salvage blood in oncological surgeries, despite literature establishing its safety. LDF is a filter device based on a membrane-like filter material used to remove leucocytes from the blood. The mechanisms underlying the removal of tumour cells are physical interception and charge adsorption based on cell size. The size of white blood cells is approximately 7–20 μm. The RLDF refers to a white blood cell filter with a pore size of 40 μm. Gray et al. conducted a prospective cohort study and found no significant difference in progression-free survival between preoperative autologous donation and IOCS-LDF groups undergoing prostatectomy [18]. Patients who undergo partial hepatectomy for colorectal cancer metastases can safely receive a transfusion of filtered autologous blood, which is not associated with an increased risk of recurrence or a higher mortality rate [19]. Patients who received a salvaged blood transfusion required significantly lesser amounts of allogeneic blood, and their survival rates and disease progression remained lower or similar to that in control patients. Furthermore, there are many studies on the clinical safety of salvage blood used in oncological surgeries, including gynaecological [20], hepatobiliary [21, 22], gastrointestinal [23], urological [18], and pulmonary [24] surgery. However, there are only a few studies on IOCS+LDF reinfusion in patients with MSTS. Gakhar et al. observed that transfusion of intraoperatively salvaged blood did not result in disseminated metastatic cancer in MSTS (level of evidence IV) [25]. More recently, Elmalky et al. demonstrated that the use of IOCS-LDF in MSTS reduces the need for postoperative ABT while maintaining satisfactory postoperative haemoglobin and they recommended routine use of IOCS-LDF in MSTS for its safety, efficacy, and potential cost benefit [4].

In this study with 20 patients, tumour cells were detected in the blood samples of 12 patients (60%) after IOCS+RLDF processing (S4), whereas it was found in
### Table 1: Patient characteristics, surgical management, and numbers of tumour cell per 4 ml blood samples

| Patient no. | Age / years | Gender | ASA status | Primary tumour | Location of the tumour | Procedure | Blood loss / ml | Blood transfusion / ml | Duration of surgery / min | Survival time / month | New metastasis / month | S1 | S2 | S3 | S4 | S5 |
|-------------|-------------|--------|------------|----------------|----------------------|-----------|----------------|------------------------|--------------------------|----------------------|----------------------|----|----|----|----|----|
| 1           | 60          | Male   | II         | Lung           | Cervical vertebra    | Decompression     | 200          | 0                      | 102                      | 3                       | 3                       | 0  | 0  | 3  | 1  |     |
| 2           | 78          | Female | II         | Lung           | Cervical vertebra    | Decompression     | 200          | 0                      | 178                      | 27                      | Unknown                | 0  | 2  | 3  | 5  |     |
| 3           | 53          | Female | I          | Breast         | Cervical vertebra    | Decompression     | 150          | 0                      | 74                       | Survival (>47)          | None                   | 2  | 1  | 0  | 0  |     |
| 4           | 44          | Female | I          | Breast         | Lumbar vertebra      | Decompression     | 600          | 0                      | 124                      | 30                      | None                   | 2  | 2  | 1  | 0  |     |
| 5           | 62          | Male   | I          | Thyroid        | Lumbar vertebra      | Debulking         | 500          | 400                    | 230                      | Survival (>42)          | 21                      | 6  | 6  | 2  | 0  |     |
| 6           | 59          | Female | II         | Thyroid        | Thoracic vertebra    | Decompression     | 200          | 0                      | 90                       | 36                      | None                   | 7  | 0  | 0  | 0  |     |
| 7           | 63          | Male   | II         | Colon          | Lumbar vertebra      | Debulking         | 200          | 0                      | 156                      | 12                      | 6                       | 8  | 3  | 4  | 1  | 2  |
| 8           | 44          | Female | II         | Colon          | Thoracic vertebra    | Debulking         | 300          | 800                    | 96                       | 10                      | 3                       | 3  | 1  | 0  | 1  |     |
| 9           | 63          | Male   | II         | Esophagus      | Cervical vertebra    | Decompression     | 400          | 800                    | 110                      | 4                       | 4                       | 1  | 2  | 0  | 0  |     |
| 10          | 69          | Male   | II         | Esophagus      | Thoracic vertebra    | Decompression     | 200          | 400                    | 87                       | 16                      | Unknown                | 3  | 2  | 1  | 1  |     |
| 11          | 50          | Male   | III        | Rectum         | Thoracic vertebra    | Decompression     | 100          | 0                      | 106                      | 6                       | Unknown                | 1  | 2  | 4  | 0  |     |
| 12          | 42          | Female | II         | Endometrium    | Cervicothoracic vertebra | Decompression     | 600          | 0                      | 137                      | Unknown                 | Unknown                | 3  | 1  | 0  | 0  |     |
| 13          | 61          | Male   | II         | Ampulla        | Lumbar vertebra      | Debulking         | 800          | 400                    | 121                      | Unknown                 | Unknown                | 1  | 1  | 2  | 1  | 0  |
| 14          | 44          | Female | II         | Breast         | Cervical vertebra    | Decompression     | 200          | 400                    | 211                      | Survival (>38)          | None                   | 2  | 1  | 1  | 2  | 0  |
| 15          | 48          | Male   | I          | Nasopharynx    | Thoracic vertebra    | Debulking         | 1000         | 800                    | 201                      | Survival (>41)          | None                   | 2  | 0  | 0  | 0  | 0  |
| 16          | 66          | Male   | II         | Renal          | Thoracic vertebra    | Debulking         | 800          | 400                    | 111                      | 21                      | Unknown                | 0  | 2  | 3  | 2  | 0  |
| 17          | 56          | Male   | II         | Lung           | Thoracic vertebra    | Debulking         | 100          | 0                      | 98                       | 18                      | Unknown                | 3  | 0  | 0  | 1  | 0  |
| 18          | 60          | Male   | II         | Lung           | Thoracic vertebra    | Debulking         | 700          | 400                    | 201                      | 32                      | 28                      | 0  | 1  | 3  | 1  | 0  |
| 19          | 66          | Male   | II         | Lung           | Thoracic vertebra    | Decompression     | 400          | 400                    | 169                      | 8                       | 4                       | 0  | 8  | 1  | 2  | 0  |
| 20          | 63          | Female | II         | Lung           | Thoracic vertebra    | Decompression     | 200          | 0                      | 166                      | 2                       | Unknown                | 0  | 1  | 1  | 2  | 1  |

S1: number of CTCs / 4ml in S1; S2: number of CTCs / 4ml in S2; S3: number of CTCs / 4ml in S3; S4: number of CTCs / 4ml in S4
venous blood before surgery (S1) in 14 (70%), in blood from the operative field (S2) in 16 (80%), and in blood after IOCS (S3) in 13 patients (65%). There was no significant difference between S4 and S1 or between S4 and S2, although a downward trend appeared after IOCS + RLDF processing (Fig. 4). This may imply that RLDF could not completely eliminate tumour cells. The “RLDF” we used did not seem to perform well compared with other published literature on IOCS with LDF in MSTS [6, 7, 26]. Our study employed the same inclusion criteria as Professor Kumar’s team, all of which were patients with a known primary epithelial tumour who underwent MSTS. In our study, leukocytes were first removed by magnetic bead sorting, and FISH technology was then used to identify chromosomal polyploidy. Different detection methods may have an impact on tumour cell recognition, resulting in poor RLDF results in our study. Consequently, new filters were added into the experiment, and got relatively satisfactory results.

Studies indicate that the pore size of the filter membrane and the wash solution are two key elements for cell depletion. Considering metastatic spine tumour derived from various types of primary tumours, the tumour cells in the blood are of different sizes. The new filter with smaller pore size was added into the experiment, and got relatively satisfactory results. MLDF was developed by a medical team in Sichuan, China. It is used for research purposes only at present and has not been commercially available. Mei et al. reported a 3–4 log reduction in leucocytes using MLDF with a pore size of 12–18 μm [8]. RLDF-treated samples were subsequently inoculated in nude mice, 67% of which developed tumours. In contrast, no tumour cells were found in MLDF-treated samples, and no solid tumours were observed in inoculated nude mice [8]. Therefore, it is considered that MLDF with mannitol-adenine-phosphate solution had higher filter efficiency, but further clinical research is warranted. Thus, we explored MLDF with a pore size of 18 μm to filter spinal metastasis tumour cells from known primary epithelial tumours. The number of tumour cells was significantly lower in the samples after MLDF processing (S5) than in the operative field (S2). We also confirmed that MLDF was more effective in eliminating tumour cells than RLDF. In this study, MLDF was more efficient for filtering tumour cells, which suggests that it may have great prospects for managing blood salvage in oncologic surgery.

Ideally, we try to eliminate all tumour cells from salvaged blood. In our study, IOCS+RLDF reduced the number of tumour cells in patients’ peripheral venous blood, but it did not eliminate them completely. MLDF achieved a much better result, clearing nearly all tumour cells.

| Table 2 Primary tumour origin and vertebral levels involved |
|----------------------------------------------------------|
| Primary tumour                     | vertebral levels involved |
| Lung - 6                           | Cervical vertebra - 5     |
| Gastrointestinal - 6               | Cervicothoracic vertebra - 1 |
| Colon - 2                          | Thoracic vertebra - 10    |
| Esophagus - 2                      | Lumbar vertebra - 4       |
| Rectum - 1                         |                           |
| Ampulla - 1                        |                           |
| Breast - 3                         |                           |
| Thyroid - 2                        |                           |
| Renal - 1                          |                           |
| Endometrium - 1                    |                           |
| Nasopharynx - 1                    |                           |

Fig. 2 The pathology images of MSTS. A Bone metastasis of breast cancer stained with hematoxylin-eosin staining (HE); B Bone metastasis of breast cancer stained with GATA3; C Bone metastasis of colon cancer stained with HE; D Bone metastasis of colon cancer stained with CK20. Scale bar = 50 μm
cells except in one case (No. 20). The patient with a primary lung cancer had the shortest survival time (2 months) and had a pathological type of low-differentiated squamous cell carcinoma, possibly suggesting that tumour cells with a high degree of malignancy can easily escape from LDF. Currently there is laboratory evidence that MLDF-filtered samples do not cause tumours in mice [8], but no evidence of clinical studies has been found. In the future, we will continue to explore the filtering effect of IOCS and LDF on MSTS from different pathological types, and hopefully propose clinical evidences for the safety of using IOCS. Karczewski et al. demonstrated that 62% of the tumour cells in blood underwent lethal trauma, whereas all the remaining tumour cells displayed morphological changes, after being processed with the IOCS device [27]. Kumar et al. reported that the tumour cells that pass through the IOCS device are morphologically altered and become nonviable and that they lose their ability to form new metastatic deposits [28]. Similar results were observed in other studies [7, 20]. Therefore, we assume that IOCS+MLDF would be an effective strategy to destroy and eliminate malignant cells and that

| History of treatment | No. of patients | No. of patients of S1 = 0(%) | No. of patients of S2 = 0(%) | No. of patients of S3 = 0(%) | No. of patients of S4 = 0(%) |
|----------------------|----------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| chemotherapy         | Yes            | 9                           | 1 (11.1)                    | 2 (22.2)                    | 3 (33.3)                    | 3 (33.3)                    |
|                      | No             | 11                          | 5 (45.5)                    | 2 (18.2)                    | 4 (36.4)                    | 5 (45.5)                    |
| Targeted therapy     | Yes            | 1                           | 0                           | 0                           | 0                           | 0                           |
|                      | No             | 19                          | 6 (31.6)                    | 4 (21.1)                    | 7 (36.8)                    | 8 (42.1)                    |
| Radiotherapy         | Yes            | 2                           | 0                           | 0                           | 0                           | 0                           |
|                      | No             | 18                          | 6 (33.3)                    | 4 (22.2)                    | 7 (38.9)                    | 8 (44.4)                    |
| Primary lesion resection | Yes             | 7                           | 1 (14.2)                    | 0                           | 2 (28.6)                    | 2 (28.6)                    |
|                      | No             | 13                          | 5 (38.5)                    | 4 (30.8)                    | 5 (38.5)                    | 6 (46.2)                    |

- **Fig. 3** Detection of tumour cells. The expression level of CD45 and the number of chromosome, such as CEP 8, CEP 17 or CEP 7 could be distinguished by immunofluorescence staining and FISH. The cells with negative CD45 expression and one or all of CEP 8, CEP 17 or CEP 7 abnormal number (number ≥ 3) were identified as circulating tumour cells. The positive expression of CD45 were discriminated as WBC. CEP 8 is the centromere signal of chromosome 8, CEP 7 is the centromere signal of chromosome 7, CEP 17 is the centromere signal of chromosome 17. Scale bar: 5 μm
salvaged autologous blood can be safely reinfused to the patient.

Strength and limitations of this study

- MLDF was applied for the first time on patients of MSTS in China.
- The salvaged blood used in this study was not reinfused to patients because of the limitations imposed by ethical issues.
- We failed to clarify the viability and functionality of the tumour cells because there were too few residual tumour cells to evaluate. And this will be a focus of our future work.

Conclusions

This study evaluated the effectiveness of IOCS combined with MLDF in MSTS. Although tumour cells could be removed by IOCS combined with RLDF from blood salvaged during MSTS, there were still residual tumour cells remaining. These findings support the notion that MLDF eliminates tumour cells more effectively than RLDF. Hence, this technique can be applied in MSTS.

Abbreviations

IOCS: Intraoperative cell salvage; MLDF: Modified leucocyte depletion filter; RLDF: Regular leucocyte depletion filter; MSTS: Metastatic spine tumour surgery; ABT: Allogeneic blood transfusion; LDF: Leucocyte depletion filter; FISH: Fluorescence in situ hybridization.

Acknowledgments

We sincerely thank all the staff of the Anesthesiology Department of Peking university third hospital for their help in this research.

Authors’ contributions

YZ and CX designed and coordinated the study, recruited the patients, collected and interpreted data, and drafted the manuscript. YG and XZ analyzed the data and performed statistical analysis. CL and BZ participated in patient recruitment and data collection. LX and HZ participated in study design. XG, FW and YL contributed to the conception of the study. All authors discussed the results, read and approved the final manuscript.

Funding

The present study was supported by Key Clinical Projects of Peking University Third Hospital (No. BYSY2017001). National Natural Science Foundation of China (No. 82002566).

Availability of data and materials

The data during this study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The study was approved by Peking university third hospital medical ethics committee (No. LM2018020) and each participant provided written informed consent.

Consent for publication

Not Applicable.

Competing interests

The authors declare that they have no competing interests.
References

1. Chen Y, Tai BC, Nayak D, Kumar N, Lim JW, Goy RWL, et al. Blood loss in
spinal tumour surgery and survival for metastatic spinal disease: a meta-
analysis. Bone Joint J. 2013;95-B:683–8.

2. Kumar N, Zaw AS, Khine HE, Maharajan K, Wai KL, Tan B, et al. Blood loss
and transfusion requirements in metastatic spinal tumor surgery: evalua-
tion of influencing factors. Ann Surg Oncol. 2016;23:2079–86.

3. Zaw AS, Kantharajanna SB, Maharajan K, Tan B, Vellayappan B, Kumar
N. Perioperative blood transfusion: does it influence survival and
cancer progression in metastatic spine tumor surgery? Transfusion.
2017;57(2):440–50.

4. Elmalky M, Yasin N, Rodrigues‑Pinto R, Stephenson J, Carroll C, Smurth‑
bridge G, et al. The safety, efficacy, and cost-effectiveness of intraoperative
cell salvage in metastatic spine tumor surgery. Spine J. 2017;17(7):872–82.

5. Kumar N, Chen Y, Zaw AS, Nayak D, Ahmed Q, Soong R, et al. Use of
intraoperative cell-salvage for autologous blood transfusions in
metastatic spine tumour surgery: a systematic review. Lancet Oncol.
2014;15(1):e33–41.

6. Kumar N, Ahmed Q, Lee VK, Chen Y, Zaw AS, Goy R, et al. Can there be a
place for intraoperative salvaged blood in spine tumor surgery? Ann Surg
Oncol. 2014;21:2436–43.

7. Kumar N, Ahmed Q, Lee VK, Zaw AS, Goy R, Wong HK. Are we ready for
the use of intraoperative salvaged blood in metastatic spine tumour surgery?
Eur Spine J. 2016;25:3997–4007.

8. Mei K, Du L, Yan M, Zhang Z, Zhang F, Gong L, et al. Modified leuko-
cyte filter removes tumor cells from the salvaged blood. PLoS One.
2015;10:e0130864.

9. Lin PP. Integrated EpCAM‑independent subtraction enrichment and iFISH
strategies to detect and classify disseminated and circulating tumors.
Clin Transl Med. 2015;4:38–44.

10. Brunelli M, Eble JN, Zhang S, Martignoni G, Cheng L. Gains of chromo-
somes 7, 17, 12, 16, and 20 and loss of Y occur early in the evolution of
papillary renal cell neoplasia: a fluorescent in situ hybridization study.
Mod Pathol. 2013;16:1053–9.

11. Sayagues JM, Abad Mdel M, Melchor HB, Gutierrez ML, Gonzalez‑Gonz‑
alez M, Jensen E, et al. Intratumoral cytogenetic heterogeneity of spo-
radic colorectal carcinomas suggests several pathways to liver metastasis.
J Pathol. 2010;221:308–19.

12. Hao JJ, Yao HQ, Dai GY, Kang W, Jia XM, Xu X, et al. Chromosomal ane-
uploidies and combinational fluorescence in situ hybridization probe
panels are useful for predicting prognosis for esophageal squamous cell
carcinoma. J Gastroenterol. 2015;50:155–66.

13. Konig JJ, Teubel W, Romijn JC, Schroder FH, Hagermeijer A. Gain and loss of
chromosomes 1, 7, 8, 10, 18, and Y in 46 prostate cancers. Hum Pathol.
1996;27:720–7.

14. Tse CH, Hwang HC, Goldstein LC, Kandalaf PL, Wiley JC, Kussick SJ, et al.
Determining true HER2 gene status in breast cancers with polysomy by
using alternative chromosome 17 reference genes: implications for anti-
HER2 targeted therapy. J Clin Oncol. 2011;29:4168–74.

15. Pennington Z, Ahmed AK, Molina CA, Ehresman J, Lauffer L, Scibba DM.
Minimally invasive versus conventional spine surgery for vertebral metas-
tases: a systematic review of the evidence. Ann Transl Med. 2018;6:103.

16. Ludwig H, Van Belle S, Barrett‑Lee P, Birgegard G, Bokemeyer C, Gascon P,
et al. The European Cancer Anaemia survey (ECAS): a large, multinational,
prospective survey defining the prevalence, incidence, and treatment of
anaemia in cancer patients. Eur J Cancer. 2004;40:2293–306.

17. Schrijvers D. Management of anemia in cancer patients: transfusions.
Oncologist. 2011;16(Suppl 3):12–8.

18. Gray CL, Amling CL, Polston GR, Powell CR, Kane CJ. Intraoperative cell
salvage in radical retropubic prostatectomy. Urology. 2001;58:740–5.

19. Kang R, Seath BE, Huang V, Barth RJ Jr. Impact of autologous blood transfu-
sion on survival and recurrence among patients undergoing partial
hepatectomy for colorectal Cancer liver metastases. J Am Coll Surg.
2019;228:902–8.

20. Catling S, Williams S, Freites O, Rees M, Davies C, Hopkins L. Use of a
leucocyte filter to remove tumour cells from intra-operative cell salvage
blood. Anaesthesia. 2008;63:1332–8.

21. Follys D, Zimmermann T, Heise M, Kaths M, Lautern A, Wisser G, et al. Liver
transplantation for hepatocellular carcinoma—is there a risk of recurrence
caused by intraoperative blood salvage autotransfusion? Eur Surg Res.
2011;47(3):182–7.

22. Liang TB, Li DL, Liang L, Li JJ, Bai XL, Yu W, et al. Intraoperative blood
salvage during liver transplantation in patients with hepatocellular carci-
noma: efficiency of leucocyte depletion filters in the removal of tumor
cells. Transplantation. 2008;85(6):963–9.

23. Bower MR, Ellis SF, Scoggins CR, McMasters KM, Martin RC. Phase II
comparison study of intraoperative autotransfusion for major oncologic
procedures. Ann Surg Oncol. 2011;18(1):166–73.

24. Perseghin P, Viganò M, Roccio G, Della Pona C, Buscemi A, Rizzi A.
Effectiveness of leucocyte filters in reducing tumor cell contamination
after intraoperative blood salvage in lung cancer patients. Vox Sang.
1997;72(4):221–4.

25. Gakhur H, Bagouni M, Bommireddy R, Kledz R. Role of intraoperative red
cell salvage and autologous transfusion in metastatic spine surgery: a pilot
study and review of literature. Asian Spine J. 2013;7:167–72.

26. Kumar N, Lam R, Zaw AS, Malhotra R, Tan J, Tan G, et al. Flow cytometric
evaluation of the safety of intraoperative salvaged blood filtered with
leucocyte depletion filter in spine tumour surgery. Ann Surg Oncol.
2014;21:4330–5.

27. Karczewski DM, Lema MJ, Glaves D. The efficiency of an autotransfu-
sion system for tumor cell removal from blood salvaged during cancer
surgery. Anesth Analg. 1994;78:1131–5.

28. Kumar N, Zaw AS, Khoo BL, Nandi S, Lai Z, Singh G, et al. Intraoperative
cell salvage in metastatic spine tumour surgery reduces potential for
reinfection of viable cancer cells. Eur Spine J. 2016;25:4008–15.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.